Everolimus does not prevent Lafora body formation in murine Lafora disease.

Neurol Genet

Department of Paediatrics (Neurology) (N.M., B.A.M.) and Program in Genetics and Genome Biology (P.W., D.G., X.Z., Y.X., B.A.M.), The Hospital for Sick Children and University of Toronto, Canada; and iC42 Clinical Research and Development (U.C.), Department of Anesthesiology, University of Colorado, Denver.

Published: February 2017

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224705PMC
http://dx.doi.org/10.1212/NXG.0000000000000127DOI Listing

Publication Analysis

Top Keywords

everolimus prevent
4
prevent lafora
4
lafora body
4
body formation
4
formation murine
4
murine lafora
4
lafora disease
4
lafora
2
everolimus
1
body
1

Similar Publications

Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project).

J Clin Med

December 2024

Pharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.

Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), is actually used to prevent organ transplant rejection and treat metastatic breast, renal, and neuroendocrine cancers. Despite significant pharmacokinetic variability among patients, routine therapeutic drug monitoring (TDM) is not commonly used in oncology. The aim of this multicenter, prospective observational cohort study is to assess the prevalence of everolimus minimum concentration at a steady state (Cminss) falling outside the therapeutic range (10-26.

View Article and Find Full Text PDF

Everolimus with or without mycophenolate mofetil for GVHD prophylaxis after allogeneic HSCT in children with acute kidney injury - a single-center retrospective analysis.

Transplant Cell Ther

January 2025

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Oncology and Hematology, Berlin, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany.

Background: Hematopoietic stem cell transplantation (HSCT) serves as a therapeutic intervention for various pediatric diseases. Acute and chronic graft-versus-host disease (GVHD) are decisive determinants for allogeneic HSCT success. The immunosuppressive agent, ciclosporin A, is most often used to prevent GVHD in pediatric patients, but is known to be nephrotoxic.

View Article and Find Full Text PDF

Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling.

J Pharm Biomed Anal

December 2024

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Leiden Network for Personalized Medicine, Leiden, the Netherlands. Electronic address:

Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice.

View Article and Find Full Text PDF

Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results.

Ann Child Neurol Soc

June 2024

Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Objective: Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants. We sought to understand the safety and potential efficacy of preventative sirolimus in infants with TSC.

View Article and Find Full Text PDF
Article Synopsis
  • - mTOR inhibitors, known for their use in cancer and immunosuppression, have shown safety in long-term use and are effective in inhibiting cell growth and regulating various biological pathways.
  • - Research indicates that these inhibitors may be beneficial for treating endometriosis by reducing hormonal therapy resistance and offering reproductive benefits like decreased miscarriage rates and improved ovarian function.
  • - While mTOR inhibitors show promise for managing endometriosis with minimal side effects, current findings are mainly from preclinical studies, and more research is required to validate their clinical effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!